Biotechnology in the Time of COVID-19: Commentaries from the Front Line

by Jeremy M. Levin

Pharmaceuticals and BIO Boards. Alnylam has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options.